Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies

Ítems similars

• Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
  per: Wasserman, Richard L., et al.
  Publicat: (2012)
• Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
  per: Wasserman, Richard L., et al.
  Publicat: (2016)
• Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
  per: Kobayashi, Roger H., et al.
  Publicat: (2019)
• Surveillance study on the tolerability and safety of Flebogamma(®) DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients
  per: Alsina, Laia, et al.
  Publicat: (2017)
• Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex(®) 10% Versus Gammaplex(®) 5% in Subjects with Primary Immunodeficiency
  per: Wasserman, Richard L., et al.
  Publicat: (2017)